Furmonertinib plus chemo for lung cancer with brain spread
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This study tests two doses of furmonertinib (a targeted pill) combined with chemotherapy for people with a specific EGFR gene change in lung cancer that has spread to the brain. It aims to see if the higher dose works better while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with a type of lung cancer called adenocarcinoma (a non-small cell lung cancer).
- Your tumor must have a specific mutation in the EGFR gene (either 19Del or L858R).
- You cannot have had prior treatment for advanced lung cancer, but if you had early-stage treatment, it must have finished more than 6 months ago.
- You must have brain metastases that are stable and not causing symptoms.
- You must be in reasonably good health (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
Hear when a new Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.